Shionogi Establishes a Developmental Subsidiary in EU Osaka, Japan, January 30, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced it has decided to establish its 100% owned subsidiary "Shionogi Limited" in London, United Kingdom as a development foothold in EU.

Shionogi has accelerated global development under the goals "globally develop at least 5 late stage (Phase IIb and beyond) products, submit NDAs overseas for 4 products (originate from Shionogi or Japanese research institutions) and launch at least one product by FY2014" during the 3rd Medium-term Business Plan. Establishment of the subsidiary aims to prepare a development foothold in EU in addition to Japan and United States to enable more efficient and rapid development by selecting the best region globally depending on stages of clinical trials.

Shionogi continues to provide innovative drugs to patients worldwide by developing its pipelines globally in 3 regions, Japan, United States and EU.